Liposomal Wnt3a Stabilization for Bone Marrow Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using Wnt proteins in bone regeneration are limited by instability and inefficiency in delivering functional Wnt3a polypeptides, which affects their ability to enhance osteogenic potential and bone growth.
Innovation Solution
A composition comprising a functionally active Wnt3a polypeptide integrated into liposomes with specific phospholipids and cholesterol, providing stability and enhanced delivery to bone marrow cells, thereby increasing expression of osteogenic markers and promoting bone growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Wnt3a polypeptide is used for bone regeneration, then osteogenic potential is enhanced, but stability and delivery efficiency are insufficient
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver Wnt3a polypeptide to bone marrow cells. The liposomal formulation serves as a mediator that protects Wnt3a from degradation and facilitates its delivery to target cells, resolving the contradiction between stability and delivery efficiency.
Solution Approach 2:
The patent modifies the physical and chemical parameters of Wnt3a by formulating it into liposomes with specific phospholipid compositions and cholesterol ratios. This parameter change transforms unstable free Wnt3a into stable liposomal encapsulated Wnt3a, improving both stability and delivery efficiency.
2Productivity
If conventional Wnt3a delivery methods are used, then some delivery occurs, but functional activity is lost due to instability
Solution Approach 1:
The patent applies beforehand cushioning by pre-encapsulating Wnt3a in liposomes before delivery. This protective encapsulation cushions Wnt3a against degradation and maintains its functional activity throughout the delivery process, preventing loss of function while ensuring delivery.
Solution Approach 2:
Liposomes act as an intermediary protective layer that maintains Wnt3a's functional activity during delivery. The liposomal membrane protects the polypeptide from environmental stressors and proteolytic degradation, ensuring it remains functional upon reaching target cells.
3Ease of manufacture
If Wnt3a is delivered without liposomal encapsulation, then delivery is simpler, but osteogenic potential is not fully realized
Solution Approach 1:
The patent changes the formulation parameters of Wnt3a by incorporating it into liposomes with specific phospholipid compositions. This parameter change enhances osteogenic potential while maintaining a relatively straightforward manufacturing process, balancing simplicity with effectiveness.
Data Source
AI summary
Disclosed herein are methods, processes, compositions, and kits for generating bone graft materials for use at a site of bone defect that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide. Also disclosed herein are methods, processes, compositions, and kits for enhancing mammalian bone marrow cells that utilizes a composition which contains liposomal Wnt polypeptide, such as liposomal Wnt3a polypeptide, liposomal Wnt5a polypeptide, or liposomal Wnt10b polypeptide.